EU generics industry slams US ‘intervention’ in SPC manufacturing waiver talks

By |oktober 23rd, 2018|Biosimilar medicines, generic drugs, generics, News, SPC manufacturing waiver|

The EU generics industry has accused the US government of intervening in the ongoing discussion in the EU on the introduction of a Supplementary Protection Certificate (SPC) manufacturing waiver.

Komentarji so izklopljeni za EU generics industry slams US ‘intervention’ in SPC manufacturing waiver talks

Access to medicines: Let’s have better care, for more patients [Sponsored]

By |oktober 18th, 2017|ageing population, Biosimilar medicines, efficiency in healthcare, generic medicine, Healthcare and austerity, healthcare systems, News, value added medicines|

Marc-Alexander Mahl is President of Medicines for Europe. Europe’s healthcare model is under pressure. Populations are ageing in Europe – with the number of Europeans aged 65 or over set to rise by 45 million between 2015 and 2050.(1) This brings with it greater healthcare costs: currently, around 50 million EU citizens are estimated to […]

Komentarji so izklopljeni za Access to medicines: Let’s have better care, for more patients [Sponsored]

New Commission study fuels generic drugs industry ‘manufacturing dispute’

By |oktober 13th, 2017|Biosimilar medicines, drugs, EFPIA, generic drugs, generics, intellectual property rights, medicines for europe, News, patent, pharmaceutical companies, pharmaceuticals|

The European Commission launched on Thursday (12 October) a public consultation on supplementary protection certificates for pharmaceutical products and the so-called Bolar patent research exemption.

Komentarji so izklopljeni za New Commission study fuels generic drugs industry ‘manufacturing dispute’

Pharma expert: EU drug agency should be ‘easily’ accessible to all

By |julij 6th, 2017|Biosimilar medicines, Brexit, Brexit negotiations, Brexit transitional deal, European Medicines Agency, generic drugs, News, personalised drugs|

Any country that wants to inherit the European Medicines Agency (EMA) from London has to be easily accessible. Candidates will also need to increase their national agency’s resources, as staff are expected to move to the EMA, according to Adrian van den Hoven.

Komentarji so izklopljeni za Pharma expert: EU drug agency should be ‘easily’ accessible to all

Pharma boss: Some EU countries effectively delay market entry of generics

By |marec 17th, 2017|Biosimilar medicines, clinical tests, drug pricing, generic drugs, medicines, News|

The harmonisation of different regulatory environments in the EU member states will help generic drugs enter the market, resulting in reduced prices for medicine and better patient access, Jacek Glinka told EURACTIV.com in an interview.

Komentarji so izklopljeni za Pharma boss: Some EU countries effectively delay market entry of generics